On the same day that Sen. Mary Landrieu took the gavel of the Senate Energy and Natural Resources Committee, a natural-gas export project in Louisiana received the green light from the Obama administration.
The two developments, which occurred just hours apart on Tuesday, are big boosts for Landrieu as she seeks reelection in Louisiana, a state that’s redder now than it was the last time she ran six years ago.
At an event in Washington, Landrieu she said she was “thrilled” about the approval. In a prepared statement, she described the announcement as “long overdue, but a welcome addition to the robust energy industry we are building in Louisiana.”
The Energy Department’s approval of the Louisiana project, owned by California-based Sempra Energy, is the sixth natural-gas export terminal that serves countries that aren’t free-trade partners with the U.S. More than 20 applications are still pending.
This announcement comes a week after Republicans on the House Energy and Commerce Committee urged the administration to speed up approval of natural-gas exports, citing economic and geopolitical benefits.
The approval could inflame a debate that’s been brewing in Washington in recent years. Sen. Debbie Stabenow, a Michigan Democrat, has expressed concern over the pace of approvals and has considered putting a hold on confirmation of a top Energy Department official because of these concerns.
Dow Chemical, an international chemical manufacturing company whose headquarters are in Michigan, has been especially vocal in opposing unfettered exports. Dow and other companies that use natural gas as a feedstock, such as aluminum-maker Alcoa, are concerned that exporting the fossil fuel could raise domestic prices, which have been near record lows because of the natural-gas boom in the last several years.
Senate Environment and Public Works ranking member David Vitter, R-La., also praised the administration’s approval on Tuesday, although he noted this isn’t the final sign-off. “This conditional approval means the Cameron LNG project has taken an important step in the right direction,” said Vitter in a statement. “I’ll continue to push for final approval to get this cutting-edge liquefied natural gas project through the cumbersome federal regulatory process.” Vitter announced last month he is running for governor in Louisiana in 2015.
What We're Following See More »
In a release Tuesday afternoon, the White House announced that President Obama has commuted and/or reduced the sentences of another 111 convicted criminals, mostly convicted of drug possession or trafficking. About 35 were serving life sentences.
Senate Judiciary Committee Chairman Chuck Grassley (R-IA) said Monday he'd now be willing to hold a hearing on Supreme Court nominee Merrick Garland in a lame-duck session of Congress. While he said he wouldn't push for it, he said if "Hillary Clinton wins the White House, and a majority of senators convinced him to do so," he would soften his previous opposition.
In a new Monmouth University poll, 46% of likely voters support Clinton and 39% back Trump, with 7% supporting Libertarian Gary Johnson, and 2% backing Jill Stein of the Green Party. That's down from a poll taken right after the Democratic convention, in which Clinton led by 13 points.
“Hillary Clinton’s advisers are talking to Donald J. Trump’s ghostwriter of The Art of the Deal, seeking insights about Mr. Trump’s deepest insecurities as they devise strategies to needle and undermine him in four weeks at the first presidential debate, the most anticipated in a generation. ... Her team is also getting advice from psychology experts to help create a personality profile of Mr. Trump to gauge how he may respond to attacks and deal with a woman as his sole adversary on the debate stage.”
The House Committee on Oversight and Government Reform has requested documents from the CEO of Mylan, "the pharmaceutical company under fire after raising the price of EpiPens more than 400 percent since 2007." Meanwhile, top members of the Energy and Commerce Committee are pressing the FDA on the lack of generic competition for EpiPens.